SBRA
Sabra Health Care REIT, Inc. [SBRA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SBRA Stock Summary
Top SBRA Correlated Resources
SBRA
Top 10 Correlated ETFs
SBRA
Top 10 Correlated Stocks
SBRA
In the News
SBRA Financial details
Company Rating
Buy
Market Cap
3.18B
Income
13.76M
Revenue
648.5M
Book val./share
12.12
Cash/share
0.2
Dividend
1.2
Dividend %
8.29%
Employees
48
Optionable
No
Shortable
Yes
Earnings
01 May 2024
P/E
243.39
Forward P/E
-
PEG
-20.71
P/S
5.17
P/B
1.19
P/C
68.03
P/FCF
16.43
Quick Ratio
2.35
Current Ratio
2.35
Debt / Equity
0.86
LT Debt / Equity
0.79
-
-
EPS (TTM)
0.06
EPS next Y
-
EPS next Q
-
EPS this Y
-117.5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-30.62%
Revenue last 5Y
-0.18%
Revenue Q/Q
1.7%
EPS Q/Q
-213.63%
-
-
-
-
SMA20
-
SMA50
7.69%
SMA100
-
Inst Own
70.95%
Inst Trans
0.82%
ROA
-
ROE
-
ROC
0.06%
Gross Margin
63%
Oper. Margin
50%
Profit Margin
2%
Payout
2017%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.3-14.91
52W High
-2.82%
52W Low
+36.05%
RSI
34
Rel Volume
0.52
Avg Volume
2.11M
Volume
1.1M
Perf Week
-1.27%
Perf Month
-2.19%
Perf Quarter
1.45%
Perf Half Y
-6.82%
-
-
-
-
Beta
1.17
-
-
Volatility
0.12%, 0.4%
Prev Close
1.3%
Price
13.605
Change
0.7%
SBRA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.54 | 2.9 | 2.6 | 2.71 | 2.84 | |
| Net income per share | 0.37 | 0.67 | -0.52 | -0.34 | 0.06 | |
| Operating cash flow per share | 1.99 | 1.72 | 1.63 | 1.37 | 1.3 | |
| Free cash flow per share | 1.99 | 1.21 | 1.47 | 1.37 | 1.33 | |
| Cash per share | 0.21 | 0.29 | 0.51 | 1.99 | 0.2 | |
| Book value per share | 18.64 | 16.53 | 15.43 | 13.23 | 12.12 | |
| Tangible book value per share | 18.1 | 16.13 | 15.18 | 13.06 | 11.99 | |
| Share holders equity per share | 18.64 | 16.53 | 15.43 | 13.23 | 12.12 | |
| Interest debt per share | 20.56 | 18.32 | 19.52 | 12.16 | 11.02 | |
| Market cap | 3.99B | 3.58B | 2.97B | 2.87B | 3.3B | |
| Enterprise value | 6.36B | 5.9B | 5.25B | 5.53B | 5.7B | |
| P/E ratio | 57.89 | 25.88 | -26.19 | -36.99 | 239.84 | |
| Price to sales ratio | 6.04 | 5.98 | 5.21 | 4.59 | 5.03 | |
| POCF ratio | 10.72 | 10.09 | 8.32 | 9.09 | 10.96 | |
| PFCF ratio | 10.72 | 14.37 | 9.19 | 9.09 | 10.77 | |
| P/B Ratio | 1.14 | 1.05 | 0.88 | 0.94 | 1.18 | |
| PTB ratio | 1.14 | 1.05 | 0.88 | 0.94 | 1.18 | |
| EV to sales | 9.61 | 9.85 | 9.22 | 8.84 | 8.69 | |
| Enterprise value over EBITDA | 12.3 | 14.11 | 26.5 | 17.09 | 13.63 | |
| EV to operating cash flow | 17.07 | 16.61 | 14.73 | 17.5 | 18.93 | |
| EV to free cash flow | 17.07 | 23.65 | 16.26 | 17.5 | 18.6 | |
| Earnings yield | 0.02 | 0.04 | -0.04 | -0.03 | 0 | |
| Free cash flow yield | 0.09 | 0.07 | 0.11 | 0.11 | 0.09 | |
| Debt to equity | 1.07 | 1.08 | 1.24 | 0.88 | 0.86 | |
| Debt to assets | 0.61 | 0.61 | 0.7 | 0.47 | 0.45 | |
| Net debt to EBITDA | 4.57 | 5.53 | 11.53 | 8.21 | 5.74 | |
| Current ratio | 2.82 | 2.25 | 4.57 | 4.31 | 2.35 | |
| Interest coverage | 2.65 | 2.4 | 0.19 | 1.29 | 1.75 | |
| Income quality | 5.4 | 2.56 | -3.15 | -4.07 | 21.89 | |
| Dividend Yield | 0.08 | 0.08 | 0.09 | 0.1 | 0.08 | |
| Payout ratio | 4.86 | 2.01 | -2.32 | -3.57 | 20.17 | |
| Sales general and administrative to revenue | 0.05 | 0.05 | 0.06 | 0.06 | 0.07 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0 | -0.3 | -0.09 | 0 | 0.02 | |
| Capex to revenue | 0 | -0.18 | -0.06 | 0 | 0.01 | |
| Capex to depreciation | 0 | -0.6 | -0.19 | 0 | 0.03 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 12.43 | 15.8 | 13.4 | 10 | 4.03 | |
| ROIC | 0.04 | 0.03 | 0 | 0.02 | 0.03 | |
| Return on tangible assets | 0.01 | 0.02 | -0.02 | -0.01 | 0 | |
| Graham Net | -12.39 | -11.07 | -9.19 | -6.95 | -9.26 | |
| Working capital | 198.17M | 182.73M | 510.09M | 470.98M | 311.89M | |
| Tangible asset value | 3.39B | 3.33B | 3.33B | 3.02B | 2.77B | |
| Net current asset value | -2.27B | -2.25B | -1.93B | -2.08B | -2.04B | |
| Invested capital | 1.07 | 1.08 | 1.24 | 0.88 | 0.86 | |
| Average receivables | 269.35M | 260.65M | 400.34M | 548.25M | 527.94M | |
| Average payables | 47.41M | 0 | 71.49M | 142.62M | 71.13M | |
| Average inventory | 29.59M | 65.58M | 95.87M | 265.59M | 229.06M | |
| Days sales outstanding | 142.21 | 160.67 | 344.27 | 326.73 | 276.36 | |
| Days payables outstanding | 0 | 0 | 369.62 | 319.31 | 0 | |
| Days of inventory on hand | 199.17 | 199.68 | 309.62 | 923.42 | 45.07 | |
| Receivables turnover | 2.57 | 2.27 | 1.06 | 1.12 | 1.32 | |
| Payables turnover | 0 | 0 | 0.99 | 1.14 | 0 | |
| Inventory turnover | 1.83 | 1.83 | 1.18 | 0.4 | 8.1 | |
| ROE | 0.02 | 0.04 | -0.03 | -0.03 | 0 | |
| Capex per share | 0 | -0.51 | -0.15 | 0 | 0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.71 | 0.7 | 0.7 | 0.7 | 0.71 | |
| Net income per share | -0.37 | -0.04 | 0.09 | -0.07 | 0.07 | |
| Operating cash flow per share | 0.29 | 0.3 | 0.3 | 0.36 | 0.34 | |
| Free cash flow per share | 0.29 | 0.3 | 0.21 | 0.01 | 0.36 | |
| Cash per share | 1.99 | 0.15 | 0.12 | 0.14 | 0.2 | |
| Book value per share | 13.23 | 12.87 | 12.73 | 12.41 | 12.12 | |
| Tangible book value per share | 13.06 | 12.7 | 12.58 | 12.27 | 11.99 | |
| Share holders equity per share | 13.23 | 12.87 | 12.73 | 12.41 | 12.12 | |
| Interest debt per share | 11.83 | 10.49 | 18.26 | 10.28 | 10.63 | |
| Market cap | 2.87B | 2.66B | 2.72B | 3.22B | 3.3B | |
| Enterprise value | 5.53B | 5.02B | 5.11B | 5.54B | 5.7B | |
| P/E ratio | -8.45 | -70.05 | 32.11 | -53.36 | 48.08 | |
| Price to sales ratio | 17.4 | 16.48 | 16.88 | 19.94 | 20.07 | |
| POCF ratio | 42.48 | 38.93 | 38.69 | 38.73 | 41.91 | |
| PFCF ratio | 42.48 | 38.93 | 55.46 | 1.25K | 39.28 | |
| P/B Ratio | 0.94 | 0.89 | 0.92 | 1.12 | 1.18 | |
| PTB ratio | 0.94 | 0.89 | 0.92 | 1.12 | 1.18 | |
| EV to sales | 33.49 | 31.13 | 31.73 | 34.27 | 34.67 | |
| Enterprise value over EBITDA | 252.65 | 48.88 | 50.23 | 53.63 | 50.52 | |
| EV to operating cash flow | 81.76 | 73.53 | 72.72 | 66.57 | 72.39 | |
| EV to free cash flow | 81.76 | 73.53 | 104.22 | 2.14K | 67.85 | |
| Earnings yield | -0.03 | 0 | 0.01 | 0 | 0.01 | |
| Free cash flow yield | 0.02 | 0.03 | 0.02 | 0 | 0.03 | |
| Debt to equity | 0.88 | 0.81 | 1.42 | 0.82 | 0.86 | |
| Debt to assets | 0.47 | 0.43 | 0.76 | 0.44 | 0.45 | |
| Net debt to EBITDA | 121.37 | 23 | 23.5 | 22.42 | 21.27 | |
| Current ratio | 4.31 | 2.61 | 4.43 | 3.79 | 2.35 | |
| Interest coverage | -1.01 | 1.75 | 2.04 | 5.29 | 1.61 | |
| Income quality | -0.8 | -7.2 | 3.32 | -5.51 | 4.59 | |
| Dividend Yield | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 | |
| Payout ratio | -0.82 | -7.31 | 3.27 | -4.59 | 4.04 | |
| Sales general and administrative to revenue | 0.19 | 0.07 | 0.06 | 0.07 | 0.1 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0 | 0 | -0.3 | -0.97 | 0.07 | |
| Capex to revenue | 0 | 0 | -0.13 | -0.5 | 0.03 | |
| Capex to depreciation | 0 | 0 | -0.48 | -1.86 | 0.12 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 10.46 | 3.45 | 5.12 | 4.27 | 4.5 | |
| ROIC | 0 | 0.01 | 0.01 | 0.03 | 0.01 | |
| Return on tangible assets | -0.01 | 0 | 0 | 0 | 0 | |
| Graham Net | -6.95 | -9.16 | -9.31 | -8.77 | -9.26 | |
| Working capital | 470.98M | 357.93M | 418.44M | 448.38M | 311.89M | |
| Tangible asset value | 3.02B | 2.94B | 2.91B | 2.84B | 2.77B | |
| Net current asset value | -2.08B | -2B | -2.04B | -1.9B | -2.04B | |
| Invested capital | 0.88 | 0.81 | 1.42 | 0.82 | 0.86 | |
| Average receivables | 524.76M | 550.56M | 524.87M | 539.06M | 533.38M | |
| Average payables | 71.13M | 71.13M | 60.93M | 60.93M | 0 | |
| Average inventory | 205.7M | 227.62M | 40.68M | 40.99M | 45.59M | |
| Days sales outstanding | 305.1 | 302.27 | 283.64 | 317.5 | 271.88 | |
| Days payables outstanding | 292.35 | 0 | 225.05 | 0 | 0 | |
| Days of inventory on hand | 845.43 | 82.53 | 69.3 | 81.95 | 45.33 | |
| Receivables turnover | 0.29 | 0.3 | 0.32 | 0.28 | 0.33 | |
| Payables turnover | 0.31 | 0 | 0.4 | 0 | 0 | |
| Inventory turnover | 0.11 | 1.09 | 1.3 | 1.1 | 1.99 | |
| ROE | -0.03 | 0 | 0.01 | -0.01 | 0.01 | |
| Capex per share | 0 | 0 | -0.09 | -0.35 | 0.02 |
SBRA Frequently Asked Questions
What is Sabra Health Care REIT, Inc. stock symbol ?
Sabra Health Care REIT, Inc. is a US stock , located in Irvine of Ca and trading under the symbol SBRA
What is Sabra Health Care REIT, Inc. stock quote today ?
Sabra Health Care REIT, Inc. stock price is $13.605 today.
Is Sabra Health Care REIT, Inc. stock public?
Yes, Sabra Health Care REIT, Inc. is a publicly traded company.
Company Profile
- Volume Average 2.11M
- Market Capitalization 3.18B
- Employee 48
- CEO Mr. Richard K. Matros
- Headquarters Irvine,CA,US
- IPO Date 2002-04-02
-
Website
https://www.sabrahealth.com 
As of March 31, 2022, Sabra's investment portfolio included 416 real estate properties held for investment. This consists of (i) 279 Skilled Nursing/Transitional Care facilities, (ii) 59 Senior Housing communities (Senior Housing - Leased), (iii) 50 Senior Housing communities operated by third-party property managers pursuant to property management agreements (Senior Housing - Managed), (iv) 13 Behavioral Health facilities and (v) 15 Specialty Hospitals and Other facilities), one asset held for sale, one investment in a sales-type lease, 16 investments in loans receivable (consisting of (i) two mortgage loans, (ii) one construction loan and (iii) 13 other loans), seven preferred equity investments and one investment in an unconsolidated joint venture. As of March 31, 2022, Sabra's real estate properties held for investment included 41,445 beds/units, spread across the United States and Canada.
